{"id":"W2286152207","doi":"10.1200/jco.2015.33.7_suppl.141","title":"Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Docetaxel; Brief Pain Inventory; Randomization; Mitoxantrone; Internal medicine; Population; Enzalutamide; Cabazitaxel; Cabozantinib; Oncology; Cancer; Randomized controlled trial; Urology; Androgen deprivation therapy; Chemotherapy; Chronic pain; Physical therapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01334682,0.001721626,0.006333002,0.0006518643,0.0004834957,0.001491251,0.001304409,0.002010144,0.009712841],"category_scores_gemma":[0.009969563,0.0007080326,0.008091518,0.000633263,0.0009324938,0.001115591,0.0006413155,0.002536069,0.001230164],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001214679,"about_ca_system_score_gemma":0.001293659,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007159165,"about_ca_topic_score_gemma":0.001267275,"domain_scores_codex":[0.993947,0.004285609,0.000334161,0.0005348795,0.0005066093,0.0003916994],"domain_scores_gemma":[0.9925951,0.003764084,0.001181714,0.0006523514,0.0006309633,0.00117579],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9830702,0.001079806,0.001496881,0.0005319903,0.002913015,0.00004200404,0.00004982393,0.0005964157,0.00200988,0.00008733722,0.0007130092,0.007409726],"study_design_scores_gemma":[0.6279558,0.3240117,0.0248134,0.000106635,0.009963675,0.0001847239,0.00008035813,0.005090882,0.003556217,0.0004716706,0.003705478,0.00005949205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9658901,0.006283494,0.003969393,0.001164994,0.0008175171,0.009791162,0.007877934,0.000380184,0.003825187],"genre_scores_gemma":[0.9791123,0.0008568753,0.003973007,0.0007731543,0.0003652798,0.005789024,0.00567736,0.00008233541,0.003370606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01334682,"threshold_uncertainty_score":0.07058561,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1474909085450899,"score_gpt":0.4478939216211045,"score_spread":0.3004030130760146,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}